Atlas market file Ā· Equity Ā· United States
Allarity Therapeutics, Inc.ALLR
- Last close
- 1.4
- Change
- +5.26%
- 96-bar range
- 1.01 ā 1.84
- As of
- 6 Aug 2026
Allarity Therapeutics, Inc. is a pharmaceutical preparations issuer listed as ALLR on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ALLR
Equity Ā· evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
ā® up candle ā® down candle
Weekly outlook: the last 104 weekly closes (-74.50% over the window).
Source rail: Yahoo Finance chart API (ALLR). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView Ā· provider feed Open view ->
Open the attributed TradingView market view for ALLR. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ALLR public profile
Pharmaceutical preparations issuer. Allarity Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Allarity Therapeutics, Inc. trades as ALLR on NASDAQ. Allarity Therapeutics, Inc. (ALLR) has a latest verified close of 1.4, up 5.26%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ALLR under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Allarity Therapeutics, Inc. today
Allarity Therapeutics (ALLR) reported a $2.8M net loss in Q1 2026, with operating cash burning at $4.5M despite touting its DRPĀ® Platform as a revolutionary cancer diagnostic tool. The companyās $19.8M cash reserves and $6.9M stockholdersā equity sit against $28M in liabilities, raising questions about sustainability without fresh funding.
As a clinical-stage precision medicine firm, Allarityās DRPĀ® technology aims to predict drug responses using gene expression profiling. While the platform is pitched as applicable to both its pipeline and broader industry drugs, the company has yet to monetize this IP meaningfully. Recent insider selling, including a $498K share disposal by CEO Lars Loennechen, contrasts with promotional claims about clinical efficiency gains.
Recent 8-K filings highlight leadership changes, including the appointment of a new CFO and director resignations. The lack of revenue, combined with $1.3M spent on R&D and minimal capex ($64K), underscores a high-risk profile. Partnerships remain critical, but evidence of tangible deals remains scarce in filings.
The stockās market mechanism hinges on trial outcomes and licensing interest in DRPĀ®. However, with no approved products and reliance on private placements for liquidity, the equity story balances on speculative execution rather than current fundamentals.
Sources & evidence Ā· 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ALLR technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ALLR
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ALLR research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. Ā£12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ALLR FAQ
What is Allarity Therapeutics, Inc. (ALLR)?Allarity Therapeutics, Inc. (ALLR) has a latest verified close of 1.4, up 5.26%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Allarity Therapeutics, Inc. (ALLR) has a latest verified close of 1.4, up 5.26%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ALLR?Allarity Therapeutics, Inc. (ALLR) has a latest verified close of 1.4, up 5.26%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Allarity Therapeutics, Inc. (ALLR) has a latest verified close of 1.4, up 5.26%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ALLR under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the ALLR page updated?The ALLR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ALLR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ALLR?The ALLR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ALLR. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ALLR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ALLR. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ALLR?Yes. The workstation can open ALLR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ALLR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ALLR page investment advice?No. The ALLR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ALLR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes ā